The Role of Gut Microbiome in the Pathogenesis of Inflammatory Diseases

Yıl 2015, Cilt: 24 Sayı: 1, 78 - 91, 17.11.2014

Tuba Koca

https://doi.org/10.17827/aktd.52576

Cited By: 1

Öz

Altered microbial composition(dysbiosis) has been correlated with a number of diseases in humans. It is nowadays proposed that the microbiome, incapable to keep up with the changes of our life-style and feeding sources, within few years might have contributed to immune imbalances. A number of studies in germ-free and antibiotic-treated animal models support causal roles for intestinal bacteria in disease susceptibility. Probiotics are defined viable microorganisms, sufficient amounts of which reach the intestine in an active state and thus exert positive health effects. The rationale and the challenges of using these probiotics in management of patients, there have been so many studies performed up. In these studies findings support probiotics as a viable therapeutic method to treat intestinal flora imbalance and diseased caused by dysbiosis.

Anahtar Kelimeler

Host-pathogen interactions, inflammatory bowel disease, pathogenicity

Bağırsak mikroflorasının inflamatuvar hastalık patogenezindeki yeri

Öz

Değişime uğramış mikroflora(disbiyoz) insanlarda pek çok hastalıklar ile ilişkilidir. Bugünlerde mikrofloranın yaşam stili, beslenme kaynaklarındaki değişime adapte olamadığı durumlarda yıllar içinde immun bozuklukların gelişmesinden sorumlu tutulmaktadır. Dış çevreden bağımsız ve antibiyotik tedavili hayvan model çalışmaları da hastalıklara yatkınlıkta intestinal bakterilerin sorumlu olabileceğini desteklemektedir. Probiyotikler bağırsak ortamına aktif durumda yeterli miktarda ulaştıklarında sağlıklı etkiler oluşturabilen etkin mikroorganizmalar olarak tanımlanmaktadır. Hastalıkların kontrolünde bu probiotiklerin kullanabilirliği gerçeği ve seçeneğini araştırmak amaçlı çalışmalar yapılmıştır. Probiotikler, intestinal flora dengesizliğinde ve disbiyozun neden olduğu hastalıklarda kullanılabilecek geçerli bir tedavi metodu olarak bu çalışmaların bulgularınca desteklenmektedir.

Anahtar Kelimeler

Enflamatuvar bağırsak hastalıkları, patojenisite, konak-patojen ilişkileri

Kaynakça

• Nazlıkul H. Detoksu Keşfet, 1. baskı. İstanbul, Alfa Basım, 2012.
• Sathyabama S, Khan N, Agrewala JN. Friendly pathogens: prevent or provoke autoimmunity. Crit Rev Microbiol. 2014;40:273-80.
• Kültürsay N. Bebeklikte barsak florası gelişimi ve immün sisteme etkileri. Çocuk Enfeksiyon Dergisi. 2009;3:75-8.
• Caicedo RA, Schanler RJ, Li N, Neu J. The developing intestinal ecosystem: İmplications for the neonate. Pediatr Res. 2005;58:625-8.
• Icaza-Chavez ME. Gut microbiota in health and disease. Rev Gastroenterol Mex. 2013;78:240-8.
• Costes LM, Boeckxstaens GE, de Jonge WJ, Callotto C. Neural networks in intestinal immunoregulation. Organogenesis. 2013;9:216-23.
• Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G et al. The role of intestinal microbiota and the immun system. Eur Rev Med Pharmacol Sci. 2013;17:323-33.
• Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, Kamm MA. The role of gut flora in health and disease and its modification as therapy. Aliment Pharmacol Ther. 2002;16:1383-93.
• Chappert P, Bouladoux N, Naik S, Schwartz RH. Specific gut commensal flora locally alters T cell turning to endogenous ligands. Immunity. 2013;38:1198-210.
• Bustos Fernandez LM, Lasa JS, Man F. Intestinal Microbiota: its role in digestive diseases. J Clin Gastroenterol. 2014;48:657-66..
• Stachowicz N, Kiersztan A. [The role of gut microbiota in the pathogenesis of obesity and diabetes]. Postepy Hig Med Dosw (Online). 2013;67:288-303.
• Dupont HL. Evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 2014;39:1033-42.
• Cahil RJ, Foltz JG, Dangler CA, Powrie F, Schauer DB. Inflammatory bowel disease: an immunity- mediated condition triggered by bacterial infection with helicobacter hepaticus. Infect Immun. 1997;65:3126-31.
• Schreiber S, Nicolaus S, Rosenstiel P. Microbiome and nutrition: the way to a future therapy for cronic inflammatory bowel diseases? Internist (Berl). 2014;55:889-97.
• Depaul-Chicoine J, Dagenals M, Saleh M. Cross-talk between the intestial microbiota and the innate immun system in intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2227-37.
• Walujkar SA, Dhotre DP, Marathe NP, Lawate PS, Bharadwaj RS et al. Characterization of bacterial communityshift in human Ulcerative Colitis patients revealed by illumina based 16S rRNA gen amplicon sequencing. Gut Pathog 201;6:22.
• Dorofeyev AE, Vasilenko IV, Rassokhina OA. Joint extraintestinal manifestations in ulcerative colitis. Dig Dis 2009;27:502-10.
• Haag LM, Fischer A, Otto B, Grundmann U, Kühl AA, Göbel UB et al. Campylobacter jejuni infection of infant mice: acute enterocolitis is folllowed by asymptomatic or symptomatic intestinal and extra-intestinal immune responses. Eur J Microbiol Immunol. 2012;2:2-11.
• Nyati KK, Nyati N. Role of Campylobacter Jejuni infections in the pathogenesis of Guillan- Barre Syndrome: an update. Biomed Res Int. 2013;2013:852195.
• Sartor RB. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther. 1997;11(Suppl 3):17-22.
• Brandzaeg P. Review article: Homing of mucosal immune cells: a possible connection between intestinal and articular inflammation. Aliment Pharmacol Ther. 1997;11(Suppl 3):24-37.
• Madupu R, Szpakowski S, Nelson KE. Microbiome in human health and disease. Sci Prog 2013;96:153-70.
• Severijnen AJ, van Kleef R, Hazenberg MP, van de Merwe JP. Chronic arthritis induced in rats by cell wall fragments of Eubacterium species from the human intestinal flora. Infect Immun. 1990;58:523-8.
• Zhang X, Rimpilainen M, Simelyte E, Toivanen P. What determines arthritogenicity of bacterial cell wall? A study on Eubacterium cell wall-induced arthritis. Rheumatology(Oxford). 2000;39:274-82.
• Yamato H, Konishi Y, Mineo S, Sekiya M, Kohno T, Kohno M. Characteristics of polyartritis in rabbits by hyperimmunization with attenuated Enterococcus faecalis. Exp Toxicol Pathol. 2000;52:247-55.
• Nieuwenhuis EE, Visser MR, Kavelaars A, Cobelens PM, Fleer A, Harmsen W et al. Oral antibiotics as a novel therapy for arthritis: evidence for benefical effect of intestinal Escherichia coli. Arthritis Rheum. 2000;43:2583-9.
• Zhang X, Zeng B, Liu Z, Liao Z, Li W, Wei H, Fang X. Comparative diversity of gut microbiota in two different human flora-associated Mouse strains. Curr Microbiol. 2014;69:365-73. .
• Gomez A, Luckey D, Yeoman CJ, Marietta EV, Berg Miller ME, Murray JA et al. Loss of sex and age driven differences in the gut microbiome characterize arthritis-suspectiple 0401 mice but not arthritis-resistant 0402 mice. PLoS One. 2012;7:e36095.
• Gul’neva M, Noskov SM. Colonic microbial biocenosis in rheumatoid arthritis. Klin Med. 2011;89:45-8.
• Michalsen A, Riegert M, Lüdtke R, Backer M, Langhorst J, Schwickert M et al. Mediterrean diet or extended fasting’s influence on changing the intestinal microflora, immunglobulin A secretion and clinical outcome in patients with rheumatoid arthritis and fibromyalgia: an observational study. BMC Complement Altern Med. 2005;22:22.
• Şendur ÖF, Aydeniz A. Spondiloartropatilerin temel özellikleri ve ayırıcı tanı ve tedavisinin genel kriterleri. ADÜ Tıp Fakültesi Dergisi 2001;2:31-5.
• Chan VS, Cohen ES, Weissensteiner T, Cheah KS, Bodmer HC. Chondrocyte antigen expression, immune response and susceptibility to arthritis. Int Immunol. 2001;13:421-9.
• Meier C, Plevy S. Therapy insight: how the gut talks to the joints: inflammatory bowel disease and the spondyloarthropathies. Nat Clin Pract Rheumatol. 2007;3:667-74.
• Nazlıkul H. Probiyotiklerin insan sağlığındaki önemi. Bayrak F. editör. Detoksu keşfet. 1. baskı. İstanbul. Alfa basım. 2012;88-94.
• de Vrese M, Schrezenmeir J. Probiotics, prebiotics and synbiotics. Adv Biochem Eng Biotechnol. 2008;1111:1-66.
• Karimi O, Pena AS. Indications and challenges of probiotics, prebiotics and synbiotics in the management of arthralgia and spondyloarthropaties in inflammatory bowel disease. J Clin Gastroenterol. 2008;42:136-41.
• Kellow NJ, Koughlan MT, Reld CM. Metbolic benefits of the dietary prebiotics in human subjects: a systematic review of randomized controlled trials. Brj Nutr 2014;111:1147-61.
• Slavin J. Fiber and prebiotics: mechanism and health benefits. Nutrients. 2013;5:1417-35.
• Samanta AK, Jayapal N, Senani S, Kolte AP, Sridhar M. Prebiotic ınulin: Usefull dietary adjuncts to manipulate the livestock gut microflora. Braz J Microbiol 2013;44:1-14.
• Tian P, Xu B, Sun H, Shi W, Li Z. A new therapies for intestinal flora imbalance used ampisilin resistant probiotics. J. Microbiol Biotechnol. 2014;24:133-296.
• Xu Z, Wang R, Yang Y, Dai R, Shang J, Yu Q. Intervention effect of probiotic bifidobacterium on type 2 diabetes mellitus rats. Wei Sheng Yan Jiu. 2014;43:277-85.
• Lohner S, Küllenberg D, Antes G, Decsi T, Meerpohl JJ. Prebiotics in healty infants and children for prevention of acute infectious diseases: a systematic review and meta-analysis. Nutr Rev. 2014;72:525-531.
• Ianiro G, Bibbo S, Gasbarrini A, Cammorota G. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr Drug Targets. 2014;15:762-70.
• Correspondence Address / Yazışma Adresi